London-based biotech Autifony has signed a £2.75m ($4.25m) collaboration deal with the universities of Newcastle and Manchester to develop treatments for schizophrenia. The bulk of the funding comes from a £1.9m award made to Autifony and the universities by UK innovation agency the Technology Strategy Board. As part of the collaboration, Autifony will provide its…
Autifony collaborates on schizophrenia
Jul 12, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Dec 14, 2023
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024